Clinical and biological effects of an agonist anti-CD40 antibody a cancer research UK phase I study

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1321-1328

  Johnson, Peter ^a   Challis, Ruth ^a   Chowdhury, Ferdousi ^a   Gao, Yifang ^a   Harvey, Melanie ^a   Geldart, Tom ^a   Kerr, Paul ^a   Chan, Claude ^a   Smith, Anna ^a   Steven, Neil ^b   Edwards, Ceri ^c   Ashton Key, Margaret ^a   Hodges, Elisabeth ^a   Tutt, Alison ^a   Ottensmeier, Christian ^a   Glennie, Martin ^a   Williams, Anthony ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHILOB7/4 ANTIBODY; COMPLEMENT COMPONENT C3D RECEPTOR; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CHILOB7-4 ANTIBODY; IL12A PROTEIN, HUMAN; IMMUNOGLOBULIN G; INTERLEUKIN 12P35; MONOCLONAL ANTIBODY;

ADULT; AGED; ANOREXIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; LARGE CELL LYMPHOMA; LARYNX SQUAMOUS CELL CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MIDDLE AGED; NATURAL KILLER CELL; NAUSEA; NON SMALL CELL LUNG CANCER; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD CD19+ B CELL; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; RIGOR; SINGLE DRUG DOSE; SOLID TUMOR; T LYMPHOCYTE; THERAPY RESISTANCE; THORAX PAIN; THYMUS CANCER; TUMOR CELL; UNITED KINGDOM; UTERINE CERVIX CANCER; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLISM; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CHEMOKINE CCL4; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-12 SUBUNIT P35; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTORS, COMPLEMENT 3D; T-LYMPHOCYTES; TRANSAMINASES;

EID: 84927615313     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2355     Document Type: Article

References (20)

1. Grewal A, Flavell R. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998;987:111-35.
2. French RR, Chan C, Tutt A, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-33.
3. Diehl L, Th. den Boer A, Schoenberger SP, van der Voort EIH, Schumacher TNM, Melief CJM, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumour-vaccine efficacy. Nat Med 1999;5:774-9.
4. Schoenberger SP, Toes RM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interaction. Nature 1998;393:480-3.
5. Geldart TR, Harvey M, Carr N, Glennie M, Johnson P. Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: evidence of preclinical efficacy. Proc ASCO 2004;14:2577.
6. Chowdhury F, Johnson PW, Glennie MJ, Williams AP. Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol Res 2014;2:229-40.
7. Chowdhury F, Tutt AL, Chan C, Glennie M, Johnson PW. Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum. J Immunol Methods 2010;363:1-8.
8. Chowdhury F, Johnson P, Williams AP. Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. Cytometry A 2010;77:328-37.
9. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009;340:55-64.
10. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83.
11. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011;187:1754-63.
12. Chowdhury F, Tutt AL, Chan C, Glennie M, Johnson PW. Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum. J Immunol Methods 2010;363:1-8.
13. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-7.
14. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013;2:e23033.
15. Carroll MC. CD21/CD35 in B cell activation. Sem Immunol 1998;10:279-86.
16. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001;167:163-72.
17. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000;18:393-422.
18. Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 2003;33:2391-7.
19. Fremeaux-Bacchi V, Fischer E, Lecoanet-Henchoz S, Mani JC, Bonnefoy JY, Kazatchkine MD. Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol 1998;10:1459-66.
20. Kubiet MA, Gonzalez-Rothi RJ, Cottey R, Bender BS. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996;110:367-70.